期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

聚乙二醇化a-干扰素药代动力学的研究

Studies on Pharmacokinetics of PEG-IFN-A
下载PDF
导出
摘要 聚乙二醇化a-干扰素已批准用于慢性丙型肝炎和慢性乙型肝炎的治疗,本文就聚乙二醇化a-干扰素的基础研究及药代动力学特性作了简要概述,其目的是提高临床医生能正确认识和理解聚乙二醇化a-干扰素的药理作用。
作者 马晔斐 杜普
机构地区 呼和浩特市第二医院药械科
出处 《北方药学》 2007年第5期42-43,32,共3页 Journal of North Pharmacy
关键词 聚乙二醇化 A-干扰素 药代动力学
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献10

  • 1吴一新,张继明.急性丙型肝炎的抗病毒治疗[J].肝脏,2006,11(4):287-289. 被引量：3
  • 2朱传武.慢性乙型肝炎的治疗、存在的问题及其展望[J].抗感染药学,2005,2(2):68-70. 被引量：7
  • 3马慧,王豪.长效干扰素:聚乙二醇干扰素研究进展[J].中华肝脏病杂志,2002,10(1):78-79. 被引量：48
  • 4Katre NV,Knauf MJ,Laird WJ.Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proceedings of the National Academy of Sciences of the United States of America . 1987
  • 5Knauf MJ,Bell DP,Hirtzer P,et al.Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. Journal of Biological Chemistry . 1988
  • 6Lam NP,Neumann AU,Gretch DR,et al.Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology . 1997
  • 7Fried MW,Shiffman ML,Reddy KR,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Homeopathy . 2002
  • 8The Italian Cooperative Study Group on Chronic Myeloid Leukemia.Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Homeopathy . 1994
  • 9Luxon,B. A.,Grace,M.,Brassard,D.Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapeutics . 2002
  • 10Z.-X. Xu,J. Hoffman,I. Patel.Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects [abstract]. Hepatology . 1998

二级参考文献33

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：735
  • 2Sandler SR, Karo W, ed. Polymer Syntheses. New York: Academic Press, 1980, 3. 138-161.
  • 3Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA, 1987, 84: 1487-1491.
  • 4Carpenter CP, Woodside MD, Kinkead ER, et al. Response of dogs to repeated intravenous injection of polyethylene glycol 4000. Toxicol Appl Pharmacol, 1971, 18: 35-40.
  • 5Abuchowski A, Davis FF. Soluble Polymer-enzyme adducts. In: Holcenberg JC, Ed. Enzymes as drugs. New York: Wiley and Sons Inc, 1981. 367-383.
  • 6Knauf MJ, Bell DP, Hirtzer P, et al. Relationship of effective molecularsize to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem, 1988, 263: 15064-15070.
  • 7Savoca K, Wieder K. Modified enzymes with unique properties. In: GB Broun, et al. Eds. Enzyme-Polyethylene glycol adducts. Vol 4. New York: Enzyme Engineering, Plenum Press. 1978. 169-173.
  • 8Mur RE. Preliminary clinical results of combination pegylated interferon α-2b plus ribavirin. In: 35th Annual meeting of the European Association for the Study of the liver. 2000, 19.
  • 9Heathcote EJ, Pockros P, Fried M, et al. The pharmacokinetics of pegylated-40 K interferon in chronic hepatitis C patients with cirrhosis. Gastroen-terology, 1999, 116(Pt2): 3190.
  • 10Glue P. Clinical pharmacology of pegylated Interferon α-2b. In: 35th Annual meeting of the European Association for the Study of the Liver. 2000, 13.

共引文献55

北方药学
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部